Sort
23,748 grants matching “melanoma”
Metabolic Vulnerabilities in Melanoma Tumors
$348,087Pere Puigserver · Dana-Farber Cancer Inst · R01 · FY2015 · CA
Effect of UVA Irradiation on Melanocyte Stem Cells and Relationship to Developmen
$347,997James D Hoerter · Ferris State University · R15 · FY2010 · ES
IN VITRO/IN VIVO ACTIVATED DENDRITIC CELLS FOR MELANOMA
$347,976University Of Southern California · R01 · FY2000 · CA
Macrophage-based ovarian cancer immunotherapy
$347,926Fiona E Yull · Vanderbilt University · R01 · FY2019 · CA
Identification of Druggable Targets to Complement Melanoma Therapy
$347,918Alan Jackson Tackett · Univ Of Arkansas For Med Scis · R01 · FY2021 · CA
Mechanisms linking hemostatic factors and malignancy
$347,828Children'S Hospital Med Ctr (Cincinnati) · R01 · FY2002 · HL
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor Therapy
$347,813John H Sampson · Duke University · R01 · FY2018 · NS
Brain Tumor Targeting Using Tumor-Specific Neuroimmunology
$347,813John H Sampson · Duke University · R01 · FY2016 · NS
Brain Tumor Targeting Using Tumor-Specific Neuroimmunology
$347,813John H Sampson · Duke University · R01 · FY2017 · NS
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor Therapy
$347,813John H Sampson · Duke University · R01 · FY2020 · NS
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor Therapy
$347,813John H Sampson · Duke University · R01 · FY2021 · NS
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor Therapy
$347,813John H Sampson · Duke University · R01 · FY2017 · NS
CCL3 as a Developmental Therapeutic to Enhance Brain Tumor Therapy
$347,813John H Sampson · Duke University · R01 · FY2019 · NS
CD91 and cancer immunosurveillance
$347,794Robert J Binder · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA
CD91 and cancer immunosurveillance
$347,794Robert J Binder · University Of Pittsburgh At Pittsburgh · R01 · FY2023 · CA
Identification of Druggable Targets to Complement Melanoma Therapy
$347,768Alan Jackson Tackett · Univ Of Arkansas For Med Scis · R01 · FY2020 · CA
Metabolic Vulnerabilities in Melanoma Tumors
$347,761Pere Puigserver · Dana-Farber Cancer Inst · R01 · FY2016 · CA
Novel Receptor-Targeting Peptides for Melanoma Therapy
$347,733Yubin Miao · University Of Colorado Denver · R01 · FY2019 · CA
Linking Genetic, Epigenetic and Signaling Mechanisms of Oncogene Addiction
$347,713Mohammad Fallahi-Sichani · University Of Virginia · R01 · FY2023 · CA
Linking Genetic, Epigenetic and Signaling Mechanisms of Oncogene Addiction
$347,709Mohammad Fallahi-Sichani · University Of Virginia · R01 · FY2022 · CA
MerTK and the Innate Immune Response to Melanoma
$347,700Henry Shelton Earp · Univ Of North Carolina Chapel Hill · R01 · FY2020 · CA
MerTK and the Innate Immune Response to Melanoma
$347,700Henry Shelton Earp · Univ Of North Carolina Chapel Hill · R01 · FY2021 · CA
MerTK and the Innate Immune Response to Melanoma
$347,700Henry Shelton Earp · Univ Of North Carolina Chapel Hill · R01 · FY2018 · CA
MerTK and the Innate Immune Response to Melanoma
$347,700Henry Shelton Earp · Univ Of North Carolina Chapel Hill · R01 · FY2017 · CA
Bone cancer and skeletal pain
$347,673University Of Minnesota Twin Cities · R01 · FY2004 · CA